Table 1.
Patient population characteristics
| Study type | Studies included in analysis | Total patients (n) | Mastectomy (%) | Breast conservation (%) | ALND (%) | SLNB (%) | Taxane chemotherapy (%) | RNI (%) |
|---|---|---|---|---|---|---|---|---|
| All Background Studies | 35 | 57,944 | 20,472 (35%) | 36,631 (63%) | 16,888 (29%) | 30,754 (53%) | 1,502 of 5,398 patients (27%)b | 2,607 of 10,184 patients (25%)b |
| Background (no monitoring studies only) | 11 | 48,833 | 18,392 (37%) | 30,246 (61%) | 12,649 (25%) | 26,058 (53%) | 533 of 2,216 patients (24%)b | 503 of 2,680 patients (18%)b |
| BIS Studies | 7 | 1,924 | 623 of 1,165 patients (53%)b | 541 of 1,165 patients (46%)† | 547 (28%) | 1125 (58%) | 314 of 948 patients (33%)b | 182 of 985 patients (18%)b |
| Circumference Studies | 11 | 8,403 | 5,362 of 5,843 patients (91%)b | 736 (8%) | 6,213 (73%) | 2019 (24%) | 32 of 71 patients (46%)b | 139 of 180 patients (77%)b |
| All Typesa | 50 | 67,712 | 26,436 (39%) | 37,858 (55%) | 23,134 (34%) | 33,845 (49%) | 1,817 of 6,383 patients (28%)b | 2,219 of 12,217 patients (18%)b |
aTotal number of patients across all study arms. Please note that Blaney, Armer, and Ridner have patients contributing to multiple arms
bVery few studies contributed. Used only the total number of patients for contributing
Note: ALND Axillary Lymph Node Dissection, SLNB Sentinel Lymph Node Biopsy, RNI Regional Node Irradiation